VP, Strategy & Program Leadership
Matthew Cardinal has more than 17 years of experience in biologics, drug, and medical device development. Matthew functions in leadership roles in the design, planning, and execution of portfolio and asset-level development strategies. Matthew has led development teams for hematology, immunology, neuromuscular, regenerative medicine, and infectious disease/vaccine programs. Matthew has recent and specific development leadership experience in AAV gene therapy for rare diseases. Matthew supports the complete development lifecycle, from discovery to registration and post-marketing, with a focus on clinical research and strategic drug development. At a technical level, Matthew is experienced in scientific writing, data analysis, and presentation.
Prior to joining Halloran, Matthew was a development lead for early-phase rare disease programs at Pfizer, where he advanced the development of marstacimab (anti-TFPI for hemophilia) and Factor Xa (hemorrhagic stroke), along with assets in sickle cell disease and gene therapies for rare immunology indications. Matthew also was a clinical development lead at Novartis, where he led development programs for meningococcal and sepsis vaccines, including a Treatment IND for a Meningitis B outbreaks with the Center for Disease Control and Prevention. Matthew has additional experience as a clinical scientist in regenerative medicine for Shire/Advanced BioHealing and as a medical device engineer for Johnson & Johnson.